drugset / Trial / NCT01007773
Safety of Dexmedetomidine in Severe Traumatic Brain Injury
Phase 2
Withdrawn
University of Maryland, Baltimore
Hospira, now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
The aim of this study is to assess the safety and feasibility of dexmedetomidine as an adjunct to conventional sedative therapy compared to conventional sedative therapy alone in patients with severe traumatic brain injury.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-01
- Completion
- 2012-01
Outcome
Outcome not reported
Stopped: “Study will not be intiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 0.4 ug/kg | — |
| Comparator | Fentanyl | Other / unclassified | — | — |
| Background | Propofol | Small molecule | 25 ug/kg | — |